Journal
CELL CYCLE
Volume 7, Issue 19, Pages 2987-2990Publisher
LANDES BIOSCIENCE
DOI: 10.4161/cc.7.19.6776
Keywords
drug discovery; hypoxia; renal cell carcinoma; synthetic lethality; targeted therapy; von Hippel-Lindau
Categories
Funding
- [NCI-CA-67166]
- [CA-82566]
- [CA-123823]
Ask authors/readers for more resources
Standard cytotoxic agents for treating cancer were developed based on their effectiveness to kill rapidly dividing cells, not on their ability to selectively kill cancer cells and spare normal tissue. Much of contemporary cancer research is aimed at identifying specific molecular features of cancers to directly target tumor cells with the hope of reducing or eliminating unwanted side effects. Targeted therapy for the treatment of cancer can be divided into two main categories: monoclonal antibodies and small molecules. In this Perspective, we review the approach of synthetic lethality to target cancer, specifically renal cell carcinoma. The concept of synthetic lethality is used to describe a genetic interaction of two non-allelic and non-lethal genes that when mutated simultaneously results in cell death. Recently, we identified a compound, STF-62247, that functions in a synthetic lethal manner to the loss of VHL, a mutation found in the majority of renal cell carcinomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available